Alumis Inc (ALMS NASDAQ) stock market data APIs
$6.0432
0.42(6.9%)
as of October 14, 2026
Try our APIs with
free plan!
Alumis Inc Financial Data Overview
Price chart is built with
Anychart
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Prev. Close
6.0432
Open
6.4596
High
6.5312
Low
6.0258
52 wk Range
4.37-31.35
Market Cap
784 M
Shares Outstanding
129 M
Revenue
7 398 K
EPS
-0.78
Beta
-0.365
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alumis Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alumis Inc data using free add-ons & libraries
Get Alumis Inc Fundamental Data
Alumis Inc Fundamental data includes:
- Net Revenue: 7 398 K
- EBITDA: -421 448 992
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -0.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alumis Inc News
New
Merck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?
Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung ...
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the...
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get Alumis Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.